Moderna has finished enrolling all 30,000 of the participants in its U.S. clinical trials for a coronavirus vaccine, putting the company on pace to have a public-ready product by December, the drugmaker announced Thursday.
All trial participants have received their first shot, with most also receiving the required second shot, CNN reported.
Dr. Stephen Hoge, the company president, said Moderna will apply for authorization from the Food and Drug Administration to enter the marketplace in early December “if all the stars align,” CNN reported.
Moderna, one of four companies currently conducting Phase 3 trials of coronavirus vaccines in the U.S., was the first to begin, starting its trial on July 27. AstraZeneca, Pfizer and Johnson & Johnson are the other companies, with Pfizer the furthest along of the three.
As of Thursday afternoon, the U.S. has approximately 8.4 million coronavirus cases and 223,000 related deaths — both tops globally — according to a Johns Hopkins University tracker.